Literature DB >> 17904464

Incidence and clinical spectrum of thiazide-associated hypercalcemia.

Robert A Wermers1, Ann E Kearns, Gregory D Jenkins, L Joseph Melton.   

Abstract

PURPOSE: The study determines the incidence of thiazide-associated hypercalcemia and clarifies its clinical features and natural history.
METHODS: In a population-based descriptive study, Olmsted County, Minn, residents with thiazide-associated hypercalcemia were identified through the Rochester Epidemiology Project and the Mayo Clinic Laboratory Information System. Changes in incidence rates were evaluated by Poisson regression.
RESULTS: Seventy-two Olmsted County residents (68 women and 4 men; mean age, 64 years) with thiazide-associated hypercalcemia first recognized in 1992 to 2001 were identified. The overall annual age- and sex-adjusted (to 2000 US whites) incidence was 7.7 (95% confidence interval [CI], 5.9-9.5) per 100,000. There was an increase in incidence after 1996, peaking at 16.3 (95% CI, 8.3-24.3) per 100,000 in 1998. The highest rate was 55.3 per 100,000 in 70- to 79-year-old women. Hypercalcemia was identified a mean of 6+/-7 years after thiazide initiation, and the average highest serum calcium was 10.7+/-0.3 mg/dL with serum parathyroid hormone (obtained in 53 patients) of 4.8+/-2.7 pmol/L. Of 33 patients who discontinued the thiazide, 21 (64%) had persistent hypercalcemia. Patients subsequently diagnosed with primary hyperparathyroidism had the highest average serum calcium and parathyroid hormone levels of 11.0+/-0.3 mg/dL and 6.3+/-2.4 pmol/L, respectively.
CONCLUSION: The persistence of hypercalcemia in patients discontinuing thiazides, and similarities in the clinical spectrum, suggest that underlying primary hyperparathyroidism is common in patients who develop hypercalcemia while taking thiazide diuretics.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17904464      PMCID: PMC2065855          DOI: 10.1016/j.amjmed.2006.07.044

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  27 in total

1.  Changes in prescribing patterns following publication of the ALLHAT trial.

Authors:  Peter C Austin; Muhammad M Mamdani; Karen Tu; Merrick Zwarenstein
Journal:  JAMA       Date:  2004-01-07       Impact factor: 56.272

2.  Hypercalcemia and primary hyperparathyroidism. Prevalence in patients receiving thiazides as detected in a health screen.

Authors:  T Christensson; K Hellström; B Wengle
Journal:  Arch Intern Med       Date:  1977-09

3.  Thiazide diuretics and calcium metabolism.

Authors:  S Middler; C Y Pak; F Murad; F C Bartter
Journal:  Metabolism       Date:  1973-02       Impact factor: 8.694

4.  The long-term effect of bendroflumethiazide on renal calcium and magnesium excretion and stone formation in patients with recurring renal stones.

Authors:  F S Jorgensen; S Brünner
Journal:  Scand J Urol Nephrol       Date:  1974

5.  Clinical findings in patients with hypercalcaemia. A final investigation based on biochemical screening.

Authors:  G Stenström; P A Heedman
Journal:  Acta Med Scand       Date:  1974-06

6.  The effect of bendroflumethiazide on the intestinal absorption of calcium in normocalcaemic renal stone formers and in hyperparathyroidism.

Authors:  F S Jorgensen; I Transbol
Journal:  Acta Med Scand       Date:  1974 Jan-Feb

7.  Hyperparathyroidism in idiopathic hypercalciuria: primary or secondary?

Authors:  F L Coe; J Canterbury; E Reiss
Journal:  Trans Assoc Am Physicians       Date:  1971

8.  Thiazide-induced parathyroid stimulation.

Authors:  J R Pickleman; F H Straus; M Forland; E Paloyan
Journal:  Metabolism       Date:  1969-10       Impact factor: 8.694

9.  changes in serum and urinary calcium during treatment with hydrochlorothiazide: studies on mechanisms.

Authors:  A S Brickman; S G Massry; J W Coburn
Journal:  J Clin Invest       Date:  1972-04       Impact factor: 14.808

10.  Enhanced parathyroid function in essential hypertension: a homeostatic response to a urinary calcium leak.

Authors:  D A McCarron; P A Pingree; R J Rubin; S M Gaucher; M Molitch; S Krutzik
Journal:  Hypertension       Date:  1980 Mar-Apr       Impact factor: 10.190

View more
  9 in total

1.  Italian Society of Endocrinology Consensus Statement: definition, evaluation and management of patients with mild primary hyperparathyroidism.

Authors:  C Marcocci; M L Brandi; A Scillitani; S Corbetta; A Faggiano; L Gianotti; S Migliaccio; S Minisola
Journal:  J Endocrinol Invest       Date:  2015-03-28       Impact factor: 4.256

2.  Thiazide-Associated Hypercalcemia: Incidence and Association With Primary Hyperparathyroidism Over Two Decades.

Authors:  Marcio L Griebeler; Ann E Kearns; Euijung Ryu; Prabin Thapa; Matthew A Hathcock; L Joseph Melton; Robert A Wermers
Journal:  J Clin Endocrinol Metab       Date:  2016-01-11       Impact factor: 5.958

3.  Primary hyperparathyroidism: Update on presentation, diagnosis, and management in primary care.

Authors:  Shelley Pallan; Aliya Khan
Journal:  Can Fam Physician       Date:  2011-02       Impact factor: 3.275

4.  Complementary and alternative medicine: a survey of its use in pediatric cardiology.

Authors:  Denise Adams; Ashley Whidden; Meeri Honkanen; Simon Dagenais; Tammy Clifford; Lola Baydala; W James King; Sunita Vohra
Journal:  CMAJ Open       Date:  2014-10-01

Review 5.  Clinical review: Prevalence and incidence of endocrine and metabolic disorders in the United States: a comprehensive review.

Authors:  Sherita H Golden; Karen A Robinson; Ian Saldanha; Blair Anton; Paul W Ladenson
Journal:  J Clin Endocrinol Metab       Date:  2009-06       Impact factor: 5.958

6.  Hyperparathyroidism with hypercalcaemia in chronic kidney disease: primary or tertiary?

Authors:  Mitchell R Lunn; Jair Muñoz Mendoza; Lezlee J Pasche; Jeffrey A Norton; Alexander L Ayco; Glenn M Chertow
Journal:  NDT Plus       Date:  2010-05-05

7.  Primary Hyperparathyroidism is Underdiagnosed and Suboptimally Treated in the Clinical Setting.

Authors:  Jacob Enell; Haytham Bayadsi; Ewa Lundgren; Joakim Hennings
Journal:  World J Surg       Date:  2018-09       Impact factor: 3.352

8.  The Relationship of Pulse Pressure and Bone Mineral Density in Adult USA Population: Analysis of the National Health and Nutritional Examination Survey.

Authors:  Isabel M McFarlane; Tai Ho Shin; Manjeet Bhamra; Milena Rodriguez Alvarez; Su Zhaz Leon; David J Ozeri; Carla Saladini; Yair Saperstein; Latoya Freeman; Muhammad A Khan; Perry Wengrofsky; Nwakile Ojike; Moro O Salifu
Journal:  Rheumatology (Sunnyvale)       Date:  2018-06-01

Review 9.  Evidence of Drug-Nutrient Interactions with Chronic Use of Commonly Prescribed Medications: An Update.

Authors:  Emily S Mohn; Hua J Kern; Edward Saltzman; Susan H Mitmesser; Diane L McKay
Journal:  Pharmaceutics       Date:  2018-03-20       Impact factor: 6.321

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.